We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Inhibikase Therapeutics Inc (IKT) USD0.001

Sell:$0.75 Buy:$0.90 Change: $0.0174 (2.34%)
Market closed |  Prices as at close on 1 July 2022 | Switch to live prices |
Change: $0.0174 (2.34%)
Market closed |  Prices as at close on 1 July 2022 | Switch to live prices |
Change: $0.0174 (2.34%)
Market closed |  Prices as at close on 1 July 2022 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing therapeutics for Parkinson’s Disease (PD) and related disorders that arise inside and outside of the brain. The Company's product candidates include IkT-148009, IkT-001Pro and IKT-01427. Its lead product candidate, IkT-148009 is a brain penetrant Abelson tyrosine kinase (c-Abl) inhibitor, that halts disease progression and reverses functional loss in the brain and reverses neurological dysfunction in the gastrointestinal (GI) tract. Its IkT-148009 is for the treatment of PD, including its manifestation in the GI tract. Its product candidate IkT-001Pro, is a prodrug of the anticancer agent Imatinibm, which is used as a treatment for chronic myelogenous leukemia (CML). IkT-01427 is an oral, brain-penetrant medication, designed to block the entry of the John Cunningham (JC) virus into the cell, thereby preventing the virus’ ability to replicate in the body.

Contact details

3350 Riverwood Parkway Se, Suite 1900
United States
+1 (678) 3923419

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$19.17 million
Shares in issue:
25.23 million
United States
US dollar

Key personnel

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.